| 0.034 0 (0%) | 05-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.47  |
1-year : | 0.74 |
| Resists | First : | 0.4 |
Second : | 0.63 |
| Pivot price | 0.38 |
|||
| Supports | First : | 0.03 |
Second : | 0.02 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.42 |
| MA(100) : | 0.94 |
MA(250) : | 1.28 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 4 |
| RSI | RSI(14): 12.9 |
|||
| 52-week | High : | 2.08 | Low : | 0.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AXDX ] has closed above bottom band by 5.8%. Bollinger Bands are 131.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.08 - 0.08 | 0.08 - 0.08 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Thu, 15 May 2025
Accelerate Diagnostics (AXDX) Options Delisted Effective May 15t - GuruFocus
Wed, 14 May 2025
Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings - Benzinga
Mon, 12 May 2025
Accelerate Diagnostics, Inc.(NasdaqCM: AXDX) dropped from S&P TMI Index - marketscreener.com
Thu, 08 May 2025
Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets - Stock Titan
Thu, 08 May 2025
Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets - PR Newswire
Wed, 26 Mar 2025
Accelerate Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 25 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 38.3 (%) |
| Held by Institutions | 18.1 (%) |
| Shares Short | 297 (K) |
| Shares Short P.Month | 359 (K) |
| EPS | -2.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.23 |
| Profit Margin | 0 % |
| Operating Margin | -281.7 % |
| Return on Assets (ttm) | -73.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -7 % |
| Gross Profit (p.s.) | 0.1 |
| Sales Per Share | 0.46 |
| EBITDA (p.s.) | -1.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | -0.02 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -0.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|